Hemogenyx Pharmaceuticals (LON:HEMO) Shares Up 1.8% – Still a Buy?

Shares of Hemogenyx Pharmaceuticals Plc (LON:HEMO) traded up 1.8% on Wednesday . The stock traded as high as GBX 370 ($4.61) and last traded at GBX 363.80 ($4.53). 11,207 shares changed hands during mid-day trading, an increase of 27% from the average session volume of 8,834 shares. The stock had previously closed at GBX 357.50 ($4.45).

Hemogenyx Pharmaceuticals Stock Performance

The company has a quick ratio of 6.72, a current ratio of 4.38 and a debt-to-equity ratio of 92.09. The stock has a market capitalization of £4.87 billion, a P/E ratio of -36,380.00 and a beta of 3.14. The business has a fifty day moving average price of GBX 258.67 and a 200-day moving average price of GBX 91.32.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.